Evropska unija - slovenščina - EMA (European Medicines Agency)

laboratorios hipra s.a. - escherichia coli j5 inactivated, staphylococcus aureus (cp8) strain sp 140 inactivated, expressing slime-associated antigenic complex - imunologija za bovidae - govedo (krave in telice) - za črede imunizacijo zdravih krav in telic, v mlekarice čred z ponavljajoče se vnetje vimena težav, da se zmanjša pojavnost sub-klinično vnetje vimena in pogostnost in resnost kliničnih znakov klinični vnetje vimena, ki jih povzročajo bakterije staphylococcus aureus, coliforms in coagulase-negativni stafilokoki. celotna imunizacijska shema povzroči imuniteto od približno 13 dni po prvi injekciji do približno 78 dni po tretji injekciji (kar ustreza 130 dni po porodu).

Evropska unija - slovenščina - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitis a virus (inactivated), hepatitis b surface antigen - immunization; hepatitis b; hepatitis a - cepiva - twinrix pediatric je indiciran za uporabo pri neimunskih dojenčkih, otrocih in mladostnikih od enega leta do vključno 15 let, pri katerih obstaja tveganje za okužbo s hepatitisom a in hepatitisom b.

Evropska unija - slovenščina - EMA (European Medicines Agency)

ceva santé animale - influenza a virus/human strain: a/jena/vi5258/2009 (h1n1)pdm09, inactivated - imunologi, inaktivirana virusna cepiva za prašiče, virus svinjske gripe - prašiči - aktivna imunizacija prašičev od starosti 8 tednov naprej proti virusu pandemičnega virusa hroščev virusa h1n1 za zmanjšanje virusne obremenitve pljuč in izločanja virusa. the vaccine can be used during pregnancy up to three weeks before expected farrowing and during lactation lactation.

Evropska unija - slovenščina - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - imunologija za suidae - prašičev (za pitanje) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Evropska unija - slovenščina - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - cepiva - active immunisation against h5 subtype of influenza a virus.

Evropska unija - slovenščina - EMA (European Medicines Agency)

ceva santé animale - inaktivirana cepiva coxiella burnetii, sev devet milj - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.

Evropska unija - slovenščina - EMA (European Medicines Agency)

laboratorios hipra, s.a. - rekombinantne serotipi, 2e e. coli - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium, immunologicals for suidae - prašiči - aktivna imunizacija pujskov iz starosti dveh dni, da se prepreči smrtnost in zmanjša klinični znaki edemske bolezni (ki jo povzroča verotoksin 2e, ki ga proizvaja e. coli) in zmanjšati izgubo dnevnega povečanja telesne mase med končnim obdobjem ob okužbah s verotoksinom 2e, ki proizvaja e. koli do zakola od 164 dni starosti.

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - e. coli adhesin f4 (f4ab, f4ac, f4ad), e. coli adhesin f5, e. coli adhesin f6, e. coli adhesin f41 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - sows; sows (nullipar) - zmanjšanje neonatalne enterotoksikoze pujskov, ki jih povzroča e. coli, izražajo adhezine f4ab, f4ac, f4ad, f5, f6 in f41, v prvih dneh življenja.

Evropska unija - slovenščina - EMA (European Medicines Agency)

intervet international bv - babesia canis, inactivated, babesia rossi, inactivated - imunologija za canidae - psi - za aktivno imunizacijo psov, starih šest mesecev ali starejših, proti babesia canis za zmanjšanje resnosti kliničnih znakov, povezanih z akutno babeziozo (b. canis) in anemijo, merjeno s pakiranim celičnim volumnom. začetek imunosti: tri tedne po osnovnem programu cepljenja. trajanje imunosti: Šest mesecev po zadnjem (ponovno)cepljenje.

Evropska unija - slovenščina - EMA (European Medicines Agency)

intervet international b.v. - prašičji cirkovirus tipa 2 orf2 podenotnega antigena - immunologicals for suidae, inactivated viral vaccines - prašiči - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by pcv2 infection.  to reduce loss of daily weight gain and mortality associated with pcv2 infection.